📊 JSPRW Key Takeaways
Is Jasper Therapeutics, Inc. (JSPRW) a Good Investment?
Jasper Therapeutics is a pre-revenue biotech company with -$246K revenue, -$83.9M operating losses, and a -$77.2M operating cash burn rate, providing only ~4.5 months of cash runway at current burn rates. The weak equity position ($4.2M vs $31.6M liabilities) and deteriorating financial trajectory indicate unsustainable fundamentals with significant default risk.
Jasper is pre-revenue with substantial operating losses (−$83.9M) and extreme negative returns on capital, indicating weak profitability. Cash of $28.7M against −$77.2M operating cash outflow implies a very short runway and high probability of external financing. While debt is zero and liquidity ratios are >2x, the thin equity base and persistent cash burn undermine financial health and growth quality.
Why Buy Jasper Therapeutics, Inc. Stock? JSPRW Key Strengths
- Strong liquidity position with 2.62x current ratio and quick ratio
- Substantial cash reserve of $28.7M providing near-term runway
- No long-term debt burden (0.00x debt/equity ratio)
- Debt-free balance sheet (0.00x), no interest burden
- Current ratio 2.62x with cash comprising most assets
- Positive equity (assets exceed liabilities), avoiding immediate insolvency
JSPRW Stock Risks: Jasper Therapeutics, Inc. Investment Risks
- Negative and declining revenue (-113.9% YoY) indicating failed commercial traction
- Massive operating losses (-$83.9M) with unsustainable cash burn of -$77.2M per period
- Critically weak stockholders' equity ($4.2M) relative to liabilities ($31.6M) creates insolvency risk
- Minimal insider activity (1 Form 4 filing in 90 days) suggests low confidence from company leadership
- Limited cash runway of approximately 4.5 months based on current burn rate
- Short cash runway given large operating cash burn
- High dilution risk from likely equity financing needs
- No recurring revenue; reported margins distorted by negative revenue and accounting volatility
Key Metrics to Watch
- Monthly operating cash burn rate and timeline to profitability or additional financing
- Revenue inflection point and path to positive revenue growth
- Stockholders' equity trend and solvency metrics
- Capital raise announcements or debt issuance to extend runway
- Operating cash flow (burn rate)
- Cash and equivalents (runway)
Jasper Therapeutics, Inc. (JSPRW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 31,366.3% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.62x current ratio provides a solid financial cushion.
JSPRW Profit Margin, ROE & Profitability Analysis
JSPRW vs Healthcare Sector: How Jasper Therapeutics, Inc. Compares
How Jasper Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Jasper Therapeutics, Inc. Stock Overvalued? JSPRW Valuation Analysis 2026
Based on fundamental analysis, Jasper Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Jasper Therapeutics, Inc. Balance Sheet: JSPRW Debt, Cash & Liquidity
JSPRW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Jasper Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.89 indicates the company is currently unprofitable.
JSPRW Revenue Growth, EPS Growth & YoY Performance
Jasper Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
JSPRW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Jasper Therapeutics, Inc. (CIK: 0001788028)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JSPRW
What is the AI rating for JSPRW?
Jasper Therapeutics, Inc. (JSPRW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JSPRW's key strengths?
Claude: Strong liquidity position with 2.62x current ratio and quick ratio. Substantial cash reserve of $28.7M providing near-term runway. ChatGPT: Debt-free balance sheet (0.00x), no interest burden. Current ratio 2.62x with cash comprising most assets.
What are the risks of investing in JSPRW?
Claude: Negative and declining revenue (-113.9% YoY) indicating failed commercial traction. Massive operating losses (-$83.9M) with unsustainable cash burn of -$77.2M per period. ChatGPT: Short cash runway given large operating cash burn. High dilution risk from likely equity financing needs.
What is JSPRW's revenue and growth?
Jasper Therapeutics, Inc. reported revenue of $-246.0K.
Does JSPRW pay dividends?
Jasper Therapeutics, Inc. does not currently pay dividends.
Where can I find JSPRW SEC filings?
Official SEC filings for Jasper Therapeutics, Inc. (CIK: 0001788028) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JSPRW's EPS?
Jasper Therapeutics, Inc. has a diluted EPS of $-3.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JSPRW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Jasper Therapeutics, Inc. has a STRONG SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JSPRW stock overvalued or undervalued?
Valuation metrics for JSPRW: ROE of -1,826.1% (sector avg: 15%), net margin of 30,813.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JSPRW stock in 2026?
Our dual AI analysis gives Jasper Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is JSPRW's free cash flow?
Jasper Therapeutics, Inc.'s operating cash flow is $-77.2M, with capital expenditures of N/A. FCF margin is 31,366.3%.
How does JSPRW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 30,813.4% (avg: 12%), ROE -1,826.1% (avg: 15%), current ratio 2.62 (avg: 2).